---
figid: PMC6701981__EMS84021-f001
figtitle: 'Muscle Wasting Diseases: Novel Targets and Treatments'
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Canis lupus familiaris
- Adeno-associated virus
- Bikinia letestui
organisms_ner:
- Rattus norvegicus
- Canis lupus familiaris
- Homo sapiens
- Mus musculus
- Danio rerio
pmcid: PMC6701981
filename: EMS84021-f001.jpg
figlink: /pmc/articles/PMC6701981/figure/F1/
number: F1
caption: 'Several classes of drugs are tested in clinical trials aimed at either inhibiting
  catabolic signaling (drug name red) and thereby reducing protein degradation (orange),
  or stimulating anabolic pathways (drug name green) and thereby increasing protein
  synthesis (blue). Activation via IGF-1, but also other upstream signals such as
  GH, androgens or β2-agonist, stimulate the PI3K – Akt – mTOR pathway and, as a consequence,
  protein synthesis is increased. In addition, Akt suppresses protein degradation
  by phosphorylating FoxO and thereby reducing its transcriptional activity. Several
  catabolic pathways do not only contribute to muscle atrophy by increasing the expression
  of E3 ligases MAFbx and MuRF1 via the transcription factors FoxO, TFEB or NF-κB,
  which all stimulate protein degradation, but also by inhibiting PI3K – Akt signaling
  and thereby reduce protein synthesis. MSTN is a major negative regulator of muscle
  mass by inhibiting Akt signaling. The multi-factorial nature of secondary muscle
  wasting and the different signaling pathways involved in muscle atrophy aggravates
  the development of effective drugs. Abbreviations not mentioned in the text: T =
  testosterone; GC = glucocorticoid'
papertitle: 'Muscle Wasting Diseases: Novel Targets and Treatments.'
reftext: Regula Furrer, et al. Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:315-339.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9361826
figid_alias: PMC6701981__F1
figtype: Figure
redirect_from: /figures/PMC6701981__F1
ndex: fc837468-df07-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6701981__EMS84021-f001.html
  '@type': Dataset
  description: 'Several classes of drugs are tested in clinical trials aimed at either
    inhibiting catabolic signaling (drug name red) and thereby reducing protein degradation
    (orange), or stimulating anabolic pathways (drug name green) and thereby increasing
    protein synthesis (blue). Activation via IGF-1, but also other upstream signals
    such as GH, androgens or β2-agonist, stimulate the PI3K – Akt – mTOR pathway and,
    as a consequence, protein synthesis is increased. In addition, Akt suppresses
    protein degradation by phosphorylating FoxO and thereby reducing its transcriptional
    activity. Several catabolic pathways do not only contribute to muscle atrophy
    by increasing the expression of E3 ligases MAFbx and MuRF1 via the transcription
    factors FoxO, TFEB or NF-κB, which all stimulate protein degradation, but also
    by inhibiting PI3K – Akt signaling and thereby reduce protein synthesis. MSTN
    is a major negative regulator of muscle mass by inhibiting Akt signaling. The
    multi-factorial nature of secondary muscle wasting and the different signaling
    pathways involved in muscle atrophy aggravates the development of effective drugs.
    Abbreviations not mentioned in the text: T = testosterone; GC = glucocorticoid'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Igf1
  - Il6
  - Igf1r
  - Tnf
  - Irs1
  - Ghr
  - Angpt1
  - Ang
  - Jak2
  - Stat3
  - Ar
  - Pik3cg
  - Creb1
  - Socs3
  - Tfeb
  - Mstn
  - Akt1
  - Smad2
  - Smad3
  - Trim63
  - Arid4b
  - Fbxo32
  - Klf15
  - Bcat2
  - Tnfrsf12a
  - Il6st
  - Nfkb1
  - IGF1
  - IL6
  - IGF1R
  - TNF
  - IRS1
  - GHR
  - ANGPT1
  - JAK2
  - STAT3
  - AR
  - SOCS3
  - TFEB
  - MSTN
  - SMAD2
  - SMAD3
  - KLF15
  - BCAT2
  - IL6ST
  - IL1B
  - JAK1
  - JAK3
  - TYK2
  - TM7SF2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PDE4A
  - PDE4B
  - PDE4C
  - PDE4D
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - NR4A3
  - OSCP1
  - AKT1
  - AKT2
  - AKT3
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - TRIM63
  - ARID4B
  - FBXO32
  - RPS6KB1
  - EIF4EBP1
  - IL1R1
  - TNFRSF12A
  - ACVR1B
  - NM
  - LRPPRC
  - IL1A
  - NFKB1
  - TNFRSF1A
  - Gh
  - Ghrl
  - Ang3
  - Tm7sf2
  - Agt
  - Pik3r1
  - Nr4a3
  - Rps6kb1
  - Eif4ebp1
  - Acvr1b
  - Il11ra1
  - Lrpprc
  - Il1
  - Tnfrsf1a
  - igf1
  - il6
  - tnfrsfa
  - tnfb
  - irs1
  - ghrl
  - ghra
  - angpt1
  - jak2b
  - stat3
  - ar
  - socs3a
  - nr4a3
  - tfeb
  - mstnb
  - smad2
  - smad3a
  - klf15
  - bcat2
  - rps6kb1b
  - il1rl1
  - acvr1ba
  - il6st
  - SUN11031
  - Anamorelin
  - Macimorelin
  - Celecoxib
  - Fosinopril
  - Ruxolitinib
  - Mk-0773
  - Losartan
  - Thalidomide
  - MSTN
  - BIIB023
  - ACE-083
  - Ly2495655
  - REGN1033
  - Cancer
---
